CPT® Code 80339

Official Description

Antiepileptics, not otherwise specified; 1-3

Common Language Description

The CPT® Code 80339 refers to a laboratory test specifically designed to measure the levels of antiepileptic drugs that are not otherwise specified. Antiepileptics are a class of medications primarily utilized in the management of seizure disorders, but they may also be prescribed for various chronic pain conditions, including migraines and fibromyalgia. The pharmacological action of these drugs can differ significantly among the various agents within this category; however, they all share a common goal of modulating brain chemistry. This modulation occurs through the alteration of several key neurotransmitter systems and ion channels, including sodium channels, GABA (gamma-aminobutyric acid) receptors, NMDA (N-methyl-D-aspartate) receptors, calcium channels, AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors, and potassium channels. By influencing these pathways, antiepileptics help to reduce the frequency of abnormal electrical discharges in the brain that can lead to seizures or pain sensations. The primary analytical techniques employed for the detection and quantification of these drugs in biological samples, such as urine, serum, or plasma, include high-performance liquid chromatography (HPLC), gas chromatography (GC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), and various immunoassays. The specific code 80339 is applicable when testing for 1-3 antiepileptic compounds, while codes 80340 and 80341 are designated for testing 4-6 and 7 or more antiepileptic drugs, respectively.

1. Indications

The laboratory test represented by CPT® Code 80339 is indicated for the measurement of antiepileptic drugs in patients who are undergoing treatment for seizure disorders or chronic pain conditions. The following conditions may warrant the use of this test:

Seizure Disorders Patients diagnosed with epilepsy or other seizure disorders may require monitoring of antiepileptic drug levels to ensure therapeutic efficacy and safety.
Migraine Individuals suffering from chronic migraines may be prescribed antiepileptics as part of their treatment regimen, necessitating regular monitoring of drug levels.
Fibromyalgia Patients with fibromyalgia may also be treated with antiepileptic medications, which may require level assessment to optimize treatment outcomes.

2. Procedure

The procedure for testing antiepileptic drug levels using CPT® Code 80339 involves several key steps, which are outlined below:

Sample Collection A biological sample, typically urine, serum, or plasma, is collected from the patient. The choice of sample type may depend on the specific antiepileptic drugs being monitored and the clinical context.
Sample Preparation The collected sample undergoes preparation, which may include processes such as centrifugation to separate plasma or serum from cellular components, or dilution to ensure the sample is suitable for analysis.
Analytical Testing The prepared sample is subjected to analytical testing using one of the primary methods, such as high-performance liquid chromatography (HPLC), gas chromatography (GC), liquid chromatography-tandem mass spectrometry (LC-MS/MS), or immunoassays. These methods are employed to accurately quantify the levels of the specified antiepileptic drugs in the sample.
Result Interpretation Once the analysis is complete, the results are interpreted by qualified laboratory personnel. The findings are then compiled into a report that indicates the concentration of the antiepileptic drugs present in the sample.

3. Post-Procedure

After the completion of the laboratory test associated with CPT® Code 80339, the following post-procedure considerations should be noted:

Patients may not require any specific post-procedure care following the collection of the sample, as the procedure is minimally invasive. However, it is essential for healthcare providers to review the test results in conjunction with the patient's clinical history and treatment plan. The results can guide adjustments to medication dosages or changes in therapeutic strategies to optimize patient outcomes. Regular monitoring may be necessary, depending on the patient's response to treatment and any side effects experienced. Additionally, healthcare providers should ensure that patients are informed about the importance of adhering to prescribed medication regimens and attending follow-up appointments for ongoing assessment.

Short Descr	ANTIEPILEPTICS NOS 1-3
Medium Descr	ANTIEPILEPTICS NOT OTHERWISE SPECIFIED 1-3
Long Descr	Antiepileptics, not otherwise specified; 1-3
Status Code	Not Valid for Medicare Purposes
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
APC Status Indicator	Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x)
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T2D - Other tests - other
MUE	1

90	Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.